Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids
Authors:
Top Cited Papers
Open Access
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 77 (5) , 644-649
Abstract
Objectives To investigate the efficacy and safety of trimethoprim/sulfamethoxazole (TMP-SMX) as primary prophylaxis for pneumocystis pneumonia (PCP) in patients with rheumatic diseases receiving high-dose steroids. Methods The study included 1522 treatment episodes with prolonged (≥4 weeks) high-dose (≥30 mg/day prednisone) steroids in 1092 patients over a 12-year period. Of these, 262 treatment episodes involved TMP-SMX (prophylaxis group) while other episodes involved no prophylaxis (control group). Differences in 1-year PCP incidence and its mortality between the two groups were estimated using Cox regression. To minimise baseline imbalance, propensity score matching was performed and efficacy outcome was mainly assessed in the postmatched population (n=235 in both groups). Results During a total of 1474.4 person-years, 30 PCP cases occurred with a mortality rate of 36.7%. One non-fatal case occurred in the prophylaxis group. TMP-SMX significantly reduced the 1-year PCP incidence (adjusted HR=0.07(95% CI 0.01 to 0.53)) and related mortality (adjusted HR=0.08 (95% CI 0.0006 to 0.71)) in the postmatched population. The result of the same analysis performed in the whole population was consistent with that of the primary analysis. Incidence rate of adverse drug reactions (ADR) related to TMP-SMX was 21.2 (14.8–29.3)/100 person-years. Only two serious ADRs (including one Stevens-Johnson syndrome case) occurred. The number needed to treat for preventing one PCP (52 (33–124)) was lower than the number needed to harm for serious ADR (131 (55–∞)). Conclusion TMP-SMX prophylaxis significantly reduces the PCP incidence with a favourable safety profile in patients with rheumatic disease receiving prolonged, high-dose steroids.Keywords
Funding Information
- National Research Foundation of Korea
This publication has 29 references indexed in Scilit:
- Pneumocystis jirovecci pneumonia in connective tissue diseases: Comparison with other immunocompromised patientsSeminars in Arthritis and Rheumatism, 2015
- Update on pulmonary Pneumocystis jirovecii infection in non-HIV patientsMedecine Et Maladies Infectieuses, 2014
- Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients with Connective Tissue DiseasesSeminars in Arthritis and Rheumatism, 2011
- Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosusRheumatology International, 2008
- When is it safe to stop Pneumocystis jiroveci pneumonia prophylaxis? Insights from three cases complicating autoimmune diseasesArthritis Care & Research, 2008
- Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: A retrospective study 2002–2004Scandinavian Journal of Infectious Diseases, 2007
- Isolation of nontuberculous mycobacteria from patients with pneumoconiosisJournal of Infection and Chemotherapy, 2005
- Pneumocystis PneumoniaNew England Journal of Medicine, 2004
- A solution to the problem of separation in logistic regressionStatistics in Medicine, 2002
- Adverse drug reactions: definitions, diagnosis, and managementThe Lancet, 2000